Featured Research

from universities, journals, and other organizations

First Canadian Bell palsy guideline

Date:
June 16, 2014
Source:
Canadian Medical Association Journal
Summary:
The first Canadian guideline for Bell palsy, facial weakness or paralysis caused by facial nerve damage, is aimed at helping physicians manage and treat patients during the acute phase as well as recovery. The guideline is based on the growing body of recent evidence on the condition.

The first Canadian guideline for Bell palsy, facial weakness or paralysis caused by facial nerve damage, is aimed at helping physicians manage and treat patients during the acute phase as well as recovery. The guideline, published in CMAJ (Canadian Medical Association Journal), is based on the growing body of recent evidence on the condition.

Bell palsy is damage to the facial nerve that results in sudden weakness or paralysis of one side of the face. It can come on suddenly with symptoms such as drooping of the face and eyelids, twitching, and others that may include mild or total paralysis.

"Although many patients with Bell palsy will experience improvement in their facial nerve function without treatment, persistent facial weakness can have implications for quality of life," writes Dr. John de Almeida and members of the Bell Palsy Working Group. "Choosing the correct treatment options for suitable patients can optimize the likelihood of recovery."

People with mild paralysis have higher rates of recovery than those who are severely affected. Because about 1 in 60 people will be affected over the course of their lifetime, it is important for primary care physicians to know how to manage this illness.

"Establishing the correct diagnosis is imperative to avoid missing another treatable condition," write the authors.

Key recommendations:

  • corticosteroids for all patients with Bell palsy to help reduce involuntary facial spasms
  • combined use of antivirals and corticosteroids in patients with severe to complete paralysis but not in patients with mild to moderate paralysis
  • no antiviral treatment alone
  • for patients who do not improve or whose symptoms worsen, referral to a specialist
  • imaging for patients who do not improve to determine if there are other causes of the weakness.

The guideline is neutral on whether physiotherapy is effective for acute weakness, but it suggests that it may help patients with persistent weakness.

"The guideline was timely given recent meta-analyses of data and recent RCTs [randomized controlled trials]," says Dr. de Almeida. "We hope this new guideline will help physicians in Canada and beyond manage Bell palsy patients."


Story Source:

The above story is based on materials provided by Canadian Medical Association Journal. Note: Materials may be edited for content and length.


Journal Reference:

  1. Joseph M. Chen et al. Management of Bell palsy: clinical practice guideline. CMAJ, June 2014 DOI: 10.1503/cmaj.131801

Cite This Page:

Canadian Medical Association Journal. "First Canadian Bell palsy guideline." ScienceDaily. ScienceDaily, 16 June 2014. <www.sciencedaily.com/releases/2014/06/140616130901.htm>.
Canadian Medical Association Journal. (2014, June 16). First Canadian Bell palsy guideline. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2014/06/140616130901.htm
Canadian Medical Association Journal. "First Canadian Bell palsy guideline." ScienceDaily. www.sciencedaily.com/releases/2014/06/140616130901.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins